InvestorsHub Logo
Followers 5
Posts 725
Boards Moderated 0
Alias Born 07/01/2017

Re: gater post# 16249

Sunday, 11/18/2018 12:06:45 AM

Sunday, November 18, 2018 12:06:45 AM

Post# of 24335
They likely can't afford the fees to file anything, the last 10-Q shows $485 in cash on hand, that's probably how much Peters had in his wallet at the time. It costs money to file. This puts the company in an interesting position.

1. They cant file anything because they can't afford it,

2. They can't raise the stock price because they can't become current,

3. A reverse split will achieve nothing because there is next to no outside interest / investor confidence here,

4. To convert the notes payable at this level would be corporate suicide since the fiscal dilution would be irreparable.

5. The only real answer is to "Go Grey" and lay low until clinical trials are done and then Peters, Chicoski, and Katzaroff can drum up interest and equity for a private placement (that is the entire reason this board was brought in in the first place, especially Katzaroff). And Peters role is to use his Washington insider status to grease the wheels of government to get the FDA to grant a form 510-K.

If I were a majority shareholder *cough Groman cough* I would be hounding the board to get going on step 5 or be shown the door and bring in better people. Also, one would assume Peters can pay these filing fees out of pocket since if the guy has enough time and money to run for Congress he has enough time and money to file some SEC docs for a small company like this.

Thanks
- DB